MoonLake Immunotherapeutics (MLTX) Short-term Investments (2020 - 2026)

MoonLake Immunotherapeutics' Short-term Investments history runs 6 years deep, the most recent figure standing at $59.4 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 71.5% year-over-year to $59.4 million; the TTM figure through Mar 2026 stood at $59.4 million (down 71.5% YoY), while the FY2025 annual figure was $59.5 million, down 77.78% from the prior year.
• Short-term Investments was $59.4 million for Q1 2026 at MoonLake Immunotherapeutics, roughly flat from $59.5 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $267.6 million in Q4 2024 to a low of $12.9 million in Q1 2023.
• Historically, Short-term Investments has averaged $103.6 million across 5 years, with a median of $88.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments slumped 87.23% in 2023, then surged 586.93% in 2024.
• A 5-year view of Short-term Investments shows it stood at $32.6 million in 2022, then surged by 83.5% to $59.8 million in 2023, then soared by 347.2% to $267.6 million in 2024, then slumped by 77.78% to $59.5 million in 2025, then decreased by 0.03% to $59.4 million in 2026.
• The last three Short-term Investments figures came in at $59.4 million (Q1 2026), $59.5 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.